Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

🤖 Plain-English Summary

BACKGROUND: The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. More than half the patients had an adverse event of grade 3 or 4.

🔑 Key Findings

• Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
• METHODS: In the phase 2 part of a phase 1-2 study, we enrolled patients with relapsed or refractory DLBCL who had received at least two lines of therapy previously.
• Patients received pretreatment with obinutuzumab to mitigate cytokine release syndrome, followed by fixed-duration glofitamab monotherapy (12 cycles total).

🔗 Related Resources